Intrommune Therapeutics, Inc.

NEW YORK, NY · Founded 2013 · Biotech · Private

Therapeutic toothpaste platform for oral delivery of food allergy treatments

Claim this profile

Follows are private to you and power your alerts

Updated · intrommune.com

Sector
Biotech
Headquarters
NEW YORK, NY
Founded
2013
Latest Form D
$3.3M, Jan 2024
Total capital
$3.5M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$3.5M
4 Form D · last Jan 2024
33 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
3 pending

Capital timeline

2018201920202021202220232024FEDERAL ↑EQUITY ↓Cumulative $25.5M1st Form D$2M2nd Form D$20M4th Form D$3.3M
2018202020222024FEDERAL ↑EQUITY ↓Cumulative $25.5M1st Form D$2M2nd Form D$20M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$3.3M
  • Private capital raisedForm D · SEC · 3rd filing$210K
  • Offering registeredForm D · SEC · 2nd filing$20M
  • Offering registeredForm D · SEC · 1st filing$2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Erick BerglundDirectorNamed in SEC Form D filings
  • Hemanshu PandyaDirectorNamed in SEC Form D filings
  • Jonathan RichDirectorNamed in SEC Form D filings
  • Michael NelsonExecutive Officer, DirectorNamed in SEC Form D filings
  • Nelson MichaelExecutive Officer, DirectorNamed in SEC Form D filings
  • William ReisacherDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 3
  • PendingMethods Of Inducing Tolerance And Reducing Adverse Reactions To One Or More Food AllergensUSPTOApplication PCTUS2024050562
  • PendingMethods Of Inducing Tolerance And Reducing Adverse Reactions In Response To Food AllergensUSPTOApplication 63589254
  • PendingMethods Of Inducing Tolerance And Reducing Adverse Reactions In Response To Food AllergensUSPTOApplication 19524879
  • ALAMAB THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
  • Alkahest, Inc.Similar federal contract value in Biotech · null in contracts
  • Evercrisp Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
  • Entheos Labs, Inc.Similar federal contract value in Biotech · null in contracts
  • Evecxia, Inc.Similar federal contract value in Biotech · null in contracts
  • Trail Software, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .